Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis

[Manouche]

 « Such deep molecular responses, to our knowledge, have never been seen in patients with myelofibrosis before,” Kiladjian noted »

 »A previously developed mathematical model for predicting long-term responses in patients with PV and ET was found to be applicable to this study and predicted a long-term decrease and potential eradication of hematopoietic stem cells »

onclive.com/view/ruxolitini...

[hunter5582]

Very interesting and hopeful outcome.